H2020Индивидуална стипендия2019–2023

OncoViroMRI · Brain Cancer Therapy Monitoring using a Novel Quantitative and Rapid Magnetic Resonance Imaging-based Method

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2019-11-01 → 2023-06-30
Финансиране от ЕС: 269 998 €
Участници: 3
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Разработва се нов метод за ЯМР образяване, който да проследи точно как се разпространяват онколитични вируси в тумори на мозъка. Това помага за по-доброто разбиране на взаимодействието между вируса и тумора и подобрява грижата за пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Brain Cancer Therapy Monitoring using a Novel Quantitative and Rapid Magnetic Resonance Imaging-based Method

Glioblastoma multiforme (GBM) is the most common type of brain tumor found in adults and is fatal in all cases. A very promising therapeutic approach for GBM is the use of oncolytic viruses (OVs) that selectively infect, replicate in, and destroy tumor cells while sparing the surrounding normal cells. Nevertheless, to achieve successful oncolytic virotherapy, frequent non-invasive monitoring of the process must be performed. This is crucial for gaining a better understanding of the interactions between the virus and its tumor-host and predicting therapeutic response. Thus, the development of a non-invasive method capable of accurately quantifying the location and extent of the viral spread in the tumor is highly required and is of great importance. Accordingly, the main research goal of this action is to develop a magnetic resonance imaging (MRI)- based method for accurate, quantitative, and rapid imaging of OVs delivery and spread in clinically relevant tumor models. The specific research objectives include developing a method for the detection and imaging of OV treatment response, increasing the specificity and sensitivity of the method using quantitative MRI techniques and machine learning, quantifying and validating the results using mouse tumor models, translating of the MRI protocols to clinical scanners, and examination of the method for additional applications. The envisioned technology could be expanded to various additional clinical conditions, and its dissemination could improve patient care. Following the project results and analysis, we conclude that a new method for noninvasive MRI of brain tumor treatment response was developed and validated (mostly in preclinical settings), demonstrating a rapid and quantitative assessment of tissue state.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Glioblastoma multiforme (GBM) is the most common type of brain tumor found in adults and is fatal in all cases. A very promising therapeutic approach for GBM is the use of oncolytic viruses (OVs) that selectively infect, replicate in, and destroy tumor cells, while sparing the surrounding normal cells. Nevertheless, to achieve successful oncolytic virotherapy, frequent non-invasive monitoring of the process must be performed. This is crucial for gaining a better understanding of the interactions between the virus and its tumor-host and predicting a therapeutic response. Thus, the development of a non-invasive method, capable of accurately quantifying the location and extent of the viral spread in the tumor is highly required and is of great importance. Accordingly, the main research goal of this action is to develop a magnetic resonance imaging (MRI)- based method for accurate, quantitative, and rapid imaging of OVs delivery, and spread in clinically relevant tumor models. The devised interdisciplinary methodology includes: genetically modifying the therapeutic virus to be detectable in MRI; developing machine learning methods to increase the speed, specificity, and sensitivity in image-monitoring the virus; and evaluating the established methods using mice models of brain tumor therapy. The allocated training and research environment is optimal for achieving the proposal goals: an outgoing phase at Harvard Medical School, a secondment at a leading clinical MRI company (Insightec), enhancing translation potential, and a return phase at a leading university (Technion), ensuring the transport of knowledge back to the EU. The envisioned technology could be expanded to various additional clinical conditions, and its dissemination could improve patient care. The unique skill set to be acquired by the experienced researcher, would allow claiming a distinct niche of knowledge, increasing competency to a tenure-track position, and a research career in the EU.

Оригинален текст от CORDIS (на английски).

Участници

TEL AVIV UNIVERSITY · Tel AvivКоординаторИзраел
Athinoula A. Martinos Center for Biomedical Imaging · CharlestownСъединени щати
TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD · HaifaИзраел